210 related articles for article (PubMed ID: 33237038)
1. Molecular subtypes based on DNA promoter methylation predict prognosis in lung adenocarcinoma patients.
Shi S; Xu M; Xi Y
Aging (Albany NY); 2020 Nov; 12(23):23917-23930. PubMed ID: 33237038
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
Li XS; Nie KC; Zheng ZH; Zhou RS; Huang YS; Ye ZJ; He F; Tang Y
BMC Cancer; 2021 Jan; 21(1):96. PubMed ID: 33485313
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method.
Cai Q; He B; Xie H; Zhang P; Peng X; Zhang Y; Zhao Z; Wang X
Cancer Med; 2020 Oct; 9(20):7488-7502. PubMed ID: 32860318
[TBL] [Abstract][Full Text] [Related]
4. Genome-scale meta-analysis of DNA methylation during progression of lung adenocarcinoma.
Zhang QH; Dai XH; Dai ZM; Cai YN
Genet Mol Res; 2015 Aug; 14(3):9200-14. PubMed ID: 26345853
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
[TBL] [Abstract][Full Text] [Related]
6. Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma.
Gan J; Huang M; Wang W; Fu G; Hu M; Zhong H; Ye X; Cao Q
J Transl Med; 2024 May; 22(1):428. PubMed ID: 38711158
[TBL] [Abstract][Full Text] [Related]
7. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of GAD1 overexpression in patients with resected lung adenocarcinoma.
Tsuboi M; Kondo K; Masuda K; Tange S; Kajiura K; Kohmoto T; Takizawa H; Imoto I; Tangoku A
Cancer Med; 2019 Aug; 8(9):4189-4199. PubMed ID: 31207151
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtypes based on DNA methylation predict prognosis in colon adenocarcinoma patients.
Yang C; Zhang Y; Xu X; Li W
Aging (Albany NY); 2019 Dec; 11(24):11880-11892. PubMed ID: 31852837
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
Li H; Tong L; Tao H; Liu Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32031203
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.
Rhee YY; Lee TH; Song YS; Wen X; Kim H; Jheon S; Lee CT; Kim J; Cho NY; Chung JH; Kang GH
Virchows Arch; 2015 Jun; 466(6):675-83. PubMed ID: 25772390
[TBL] [Abstract][Full Text] [Related]
12. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
13. A functional methylation signature to predict the prognosis of Chinese lung adenocarcinoma based on TCGA.
Wang K; Liu Y; Lu G; Xiao J; Huang J; Lei L; Peng J; Li Y; Wei S
Cancer Med; 2022 Jan; 11(1):281-294. PubMed ID: 34854250
[TBL] [Abstract][Full Text] [Related]
14. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.
Xu F; He L; Zhan X; Chen J; Xu H; Huang X; Li Y; Zheng X; Lin L; Chen Y
Aging (Albany NY); 2020 Nov; 12(24):25275-25293. PubMed ID: 33234739
[TBL] [Abstract][Full Text] [Related]
16. Aberrant CpG-methylation affects genes expression predicting survival in lung adenocarcinoma.
He W; Ju D; Jie Z; Zhang A; Xing X; Yang Q
Cancer Med; 2018 Nov; 7(11):5716-5726. PubMed ID: 30353687
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
[No Abstract] [Full Text] [Related]
18. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
19. Frequent silencing of the candidate tumor suppressor TRIM58 by promoter methylation in early-stage lung adenocarcinoma.
Kajiura K; Masuda K; Naruto T; Kohmoto T; Watabnabe M; Tsuboi M; Takizawa H; Kondo K; Tangoku A; Imoto I
Oncotarget; 2017 Jan; 8(2):2890-2905. PubMed ID: 27926516
[TBL] [Abstract][Full Text] [Related]
20. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
